Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kintara Therapeutics, Inc. (DMPI) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kintara Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1498382.
Total stock buying since 2014: $556,429.
Total stock sales since 2014: $0.
Total stock option exercises since 2014: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2022 | 55,000 | $25,795 | 0 | $0 | 0 | $0 |
| 2021 | 81,700 | $52,983 | 0 | $0 | 0 | $0 |
| 2020 | 377,760 | $0 | 0 | $0 | 0 | $0 |
| 2019 | 35,000 | $23,730 | 0 | $0 | 0 | $0 |
| 2017 | 160,684 | $244,277 | 0 | $0 | 0 | $0 |
| 2015 | 283,666 | $178,626 | 0 | $0 | 0 | $0 |
| 2014 | 36,985 | $31,018 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2022-02 | 55,000 | $25,795 | 0 | $0 | 0 | $0 |
| 2021-12 | 78,700 | $50,757 | 0 | $0 | 0 | $0 |
| 2021-11 | 3,000 | $2,226 | 0 | $0 | 0 | $0 |
| 2020-08 | 377,760 | $0 | 0 | $0 | 0 | $0 |
| 2019-09 | 35,000 | $23,730 | 0 | $0 | 0 | $0 |
| 2017-11 | 80,900 | $66,746 | 0 | $0 | 0 | $0 |
| 2017-10 | 27,500 | $23,660 | 0 | $0 | 0 | $0 |
| 2017-06 | 45,784 | $128,371 | 0 | $0 | 0 | $0 |
| 2017-05 | 2,500 | $5,500 | 0 | $0 | 0 | $0 |
| 2017-02 | 4,000 | $20,000 | 0 | $0 | 0 | $0 |
| 2015-11 | 7,500 | $11,025 | 0 | $0 | 0 | $0 |
| 2015-10 | 3,000 | $2,370 | 0 | $0 | 0 | $0 |
| 2015-09 | 4,000 | $3,320 | 0 | $0 | 0 | $0 |
| 2015-07 | 261,666 | $156,999 | 0 | $0 | 0 | $0 |
| 2015-01 | 7,500 | $4,912 | 0 | $0 | 0 | $0 |
| 2014-12 | 2,500 | $2,250 | 0 | $0 | 0 | $0 |
| 2014-11 | 10,500 | $9,900 | 0 | $0 | 0 | $0 |
| 2014-09 | 23,985 | $18,868 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-02-15 | Hoffman Robert E. (President and CEO) | Buy | 55,000 | .47 | 25,795 |
| 2021-12-08 | Praill Anthony Scott (Chief Financial Officer) | Buy | 28,700 | .68 | 19,429 |
| 2021-12-07 | Zarrabian Saiid (Head of Strategic Partnerships) | Buy | 38,109 | .64 | 24,313 |
| 2021-12-06 | Zarrabian Saiid (Head of Strategic Partnerships) | Buy | 11,891 | .59 | 7,015 |
| 2021-11-22 | Johnson Laura L. (Director) | Buy | 3,000 | .74 | 2,226 |
| 2020-08-19 | Liatos John (SVP, Business Development) | Buy | 196,750 | .00 | 0 |
| 2020-08-19 | Murphy Keith | Buy | 181,010 | .00 | 0 |
| 2019-09-13 | Bell John K | Buy | 35,000 | .68 | 23,730 |
| 2017-11-16 | Bell John K | Buy | 18,129 | .81 | 14,684 |
| 2017-11-15 | Bell John K | Buy | 1,871 | .81 | 1,515 |
| 2017-11-14 | Zarrabian Saiid (Interim CEO) | Buy | 60,900 | .83 | 50,547 |
| 2017-10-06 | Bacha Jeffrey (CEO) | Buy | 10,000 | .88 | 8,750 |
| 2017-10-05 | Praill Scott (Chief Financial Officer) | Buy | 17,500 | .85 | 14,910 |
| 2017-06-26 | Cranston Lynda Sarah | Buy | 2,083 | 3.60 | 7,498 |
| 2017-06-26 | Bell John K | Buy | 4,167 | 3.60 | 15,001 |
| 2017-06-26 | Bacha Jeffrey (CEO) | Buy | 6,700 | 3.60 | 24,120 |
| 2017-06-26 | Praill Scott (Chief Financial Officer) | Buy | 4,167 | 3.60 | 15,001 |
| 2017-06-26 | Mohr Erich | Buy | 4,167 | 3.60 | 15,001 |
| 2017-06-06 | Bell John K | Buy | 10,000 | 2.12 | 21,200 |
| 2017-06-06 | Bacha Jeffrey (CEO) | Buy | 5,000 | 2.12 | 10,600 |
| 2017-06-06 | Praill Scott (Chief Financial Officer) | Buy | 9,500 | 2.10 | 19,950 |
| 2017-05-05 | Bacha Jeffrey (Chief Executive Officer) | Buy | 2,500 | 2.20 | 5,500 |
| 2017-02-01 | Bacha Jeffrey (CEO) | Buy | 4,000 | 5.00 | 20,000 |
| 2015-11-25 | Bacha Jeffrey (CEO, Director) | Buy | 7,500 | 1.47 | 11,025 |
| 2015-10-08 | Bacha Jeffrey (President, CEO) | Buy | 3,000 | .79 | 2,370 |
| 2015-09-18 | Bacha Jeffrey (President, CEO) | Buy | 4,000 | .83 | 3,320 |
| 2015-07-25 | Brown Dennis M (Chief Scientific Officer) | Buy | 10,000 | .60 | 6,000 |
| 2015-07-25 | Bacha Jeffrey (President, CEO) | Buy | 10,000 | .60 | 6,000 |
| 2015-07-22 | Brown Dennis M (Chief Scientific Officer) | Buy | 75,000 | .60 | 45,000 |
| 2015-07-16 | Bell John K | Buy | 50,000 | .60 | 30,000 |
| 2015-07-16 | Bacha Jeffrey (President, CEO) | Buy | 50,000 | .60 | 30,000 |
| 2015-07-16 | Garner William J | Buy | 16,666 | .60 | 9,999 |
| 2015-07-16 | Praill Scott (Chief Financial Officer) | Buy | 50,000 | .60 | 30,000 |
| 2015-01-22 | Bacha Jeffrey (CEO and President) | Buy | 7,500 | .66 | 4,912 |
| 2014-12-09 | Bacha Jeffrey (CEO and President) | Buy | 2,500 | .90 | 2,250 |
| 2014-11-26 | Bacha Jeffrey (CEO and President) | Buy | 2,500 | .92 | 2,300 |
| 2014-11-21 | Bell John K (Director) | Buy | 8,000 | .95 | 7,600 |
| 2014-09-18 | Bacha Jeffrey (CEO and President) | Buy | 4,000 | .98 | 3,920 |
| 2014-09-15 | Bacha Jeffrey (CEO and President) | Buy | 4,985 | .75 | 3,738 |
| 2014-09-08 | Bell John K (Director) | Buy | 7,000 | .71 | 4,970 |
| 2014-09-04 | Bell John K (Director) | Buy | 8,000 | .78 | 6,240 |
Insider trading activities including stock purchases, stock sales, and option exercises of DMPI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kintara Therapeutics, Inc. (symbol DMPI, CIK number 1498382) see the Securities and Exchange Commission (SEC) website.